HMGCR and osteoporosis: Lipid-lowering variants of HMGCR (OR 1.01; 95% CI: 1.004 to 1.02; p-IVW=1.39×10-3, FDR=7.27×10-3) were associated with a slightly increased risk of osteoporosis whereas PCKS9 (OR 0.99; 95% CI: 0.99 to 0.997; p-IVW=9.89×10-4, FDR=5.75×10-3) was associated with decreased risks of osteoporosis.